Abbott, Tandem Diabetes Care Move Ahead to Develop Technologies for Automated Insulin Delivery Systems
June 29 2020 - 9:58AM
Dow Jones News
By Robb M. Stewart
Abbott Laboratories has finalized a deal with Tandem Diabetes
Care Inc. to work together on automated insulin delivery
systems.
Abbott said the companies will develop and commercialize systems
that combine its continuous glucose monitoring technology with
Tandem's insulin delivery systems to provide more options for
people to manage their diabetes.
The companies first announced plans to work together in late
2019. The agreement covers technical development of device
integration and associated commercial support activities.
Abbott and Tandem Diabetes Care will focus their initial
commercial activities in the U.S. and Canada, with additional
geographies considered in the future.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
June 29, 2020 09:43 ET (13:43 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Sep 2023 to Sep 2024